Lundbeck loses Israeli patent extension for Cipralex
This article was originally published in Scrip
Executive Summary
The district court of Jerusalem has upheld the decision of the Israeli patent office which declined to extend the term of the patent (SPC) covering Lundbeck's antidepressant, Cipralex, which contains the S-enantiomer (escitalopram) of the racemate citalopram.